Skip to main content

Table 1 List of indicators employed in the Polish National Oncology Network

From: The pilot project of the National Cancer Network in Poland: Assessment of the functioning of the National Cancer Network and results from quality indicators for lung cancer (2019–2021)

Indicator

Description

F_0a

Multidisciplinary tumour boards assess the completeness of the diagnostics

F_1

The percentage of deaths within one year from the diagnosis of a malignant neoplasm, correlated to tumour stage

F_2

The percentage of deaths within 30 days from the date of surgery, correlated to tumour stage

F_3

Percentage of deaths within 30 days from the end of chemotherapy, correlated to tumour stage

F_4

Percentage of deaths within 30 days from the end of palliative radiotherapy, correlated to tumour stage

F_5

Percentage of patients requiring hospitalisation due to complications after surgical treatment

F_6

Percentage of patients requiring hospitalisation due to complications after radiotherapy

F_7

Percentage of patients requiring hospitalisation due to complications after systemic treatment

F_8

Percentage of patients who received chemotherapy during inpatient hospitalisation

F_9

Percentage of stage III and IV cancer patients

F_10

Assessment of the completeness of a pathological exam

F_11_1

Percentage of patients with genetic and molecular testing for predictive factors (colorectal cancer)

F_11_2

Percentage of patients with genetic and molecular testing for predictive factors (lung cancer)

F_11_3

Percentage of patients with genetic and molecular testing for predictive factors; immunohistochemistry only (breast cancer)

F_11_4

Percentage of patients with genetic and molecular testing for predictive factors (breast cancer)

F_11_5

Percentage of patients with genetic and molecular testing for predictive factors; FISH only (breast cancer)

F_11_6

Percentage of patients with genetic and molecular testing for predictive factors (ovarian cancer)

F_11_7

Percentage of patients with genetic and molecular testing for predictive factors; immunohistochemistry only (DCIS)

F_11_8

Percentage of patients with genetic and molecular testing for predictive factors (DCIS)

F_12_1

The percentage of surgical procedures performed with minimally invasive surgery (colorectal cancer)

F_12_2

The percentage of surgical procedures performed with minimally invasive surgery (lung cancer)

F_12_3

The percentage of surgical procedures performed with minimally invasive surgery (ovarian cancer)

F_12_4

The percentage of surgical procedures performed with minimally invasive surgery (prostate cancer)

F_13

Median time elapsed from the date of registration of the patient for a diagnostic (imaging or pathomorphological) exam to the date of obtaining the result of this exam

F_14

Percentage of repeated diagnostic tests over a 6-week period (computed tomography, endoscopy, biopsy, pathomorphological assessment, molecular assessment), shown for each participating centre by tumour type and test type

F_15

Percentage of repeated surgical treatments fordiagnoses other thanbreast cancer

F_16

Percentage of patients with rectal cancer who received preoperative radiotherapy

F_17

Proportion of postoperative histopathology assessment in patients with colorectal cancer with at least 12 lymph nodes assessed

F_18

The rate of anastomotic leakage in colon and rectal cancer

F_19

Assessment of the number of lymph nodes removed during prostatectomy

F_20

The percentage of pelvic lymphadenectomy performedaccording to anatomical ranges

F_21

Amounts of positive postoperative margins after prostatectomy

F_22

Percentage of patients with suspected lung cancer consulted by a pulmonologist within 14 working days from the date of registering the referral with the service provider

F_23

The proportion of patients with mediastinal lymphadenopathy greater than 10 mm who underwent EBUS-TBNA

F_24

The proportion of patients with suspected lung cancer and pleural effusion diagnosed with fluid aetiology

F_25

The proportion of patients with stage III non-small-cell lung cancerwho received concurrent chemoradiotherapy

F_26

The proportion of ovarian cancer patients treated with primary optimal or suboptimal cytoreduction (no residual mass or ≤ 1 cm)

F_27

The proportion of patients with ovarian cancer who received neoadjuvant chemotherapy

F_28

Percentage of patients with ovarian cancer who underwent exploratory laparotomy

F_29

The proportion of patients with non-infiltrating breast neoplasms not larger than 2 cm in diameter (excluding patients with BRCA1 and BRCA2 mutations) undergoing breast-conserving therapy

F_30

The proportion of patients with infiltrative breast neoplasm not exceeding 3 cm in diameter (total size, including the DCIS component; after excluding patients with BRCA1 and BRCA2 mutations) undergoing breast-conserving treatment

F_31

Percentage of diagnostic tests requiring redescription orreverification of the material over a 6-week period (computedtomography, pathomorphological assessment, molecular assessment),shown for each participating centre by tumour type and test type

F_32

Percentage of DCIS breast patients with no axillary lymphadenectomy

F_33

The proportion of patients with invasive breast neoplasm withoutlymph node metastases (pN0) without axillary lymphadenectomy

F_34

Percentage of patients with ER-positive and PR-positive infiltrating breast cancer who received hormone therapy

F_35

The percentage of patients with inflammatory or locally advanced, unresectable breast cancer

  1. abold in the text measures used for evaluating lung cancer patients